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To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five –amino-acid peptide derived from the synergy
region of fibronectin, adult patients with advanced solid tumours were enrolled in eight sequential dose cohorts (0.1–16mgkg
 1),
receiving ATN-161 administered as a 10-min infusion thrice weekly. Pharmacokinetic sampling of blood and urine over 7h was
performed on Day 1. Twenty-six patients received from 1 to 14 4-week cycles of treatment. The total number of cycles administered
to all patients was 86, without dose-limiting toxicities. At dose levels above 0.5mgkg
 1, mean total clearance and volume of
distribution showed dose-independent pharmacokinetics (PKs). At 8.0 and 16.0mgkg
 1, clearance of ATN-161 was reduced,
suggesting saturable PKs. Dose escalation was halted at 16mgkg
 1 when drug exposure (area under the curve) exceeded that
associated with efficacy in animal models. There were no objective responses. Six patients received more than four cycles of
treatment (4112 days). Three patients received 10 or more cycles (X280 days). ATN-161 was well tolerated at all dose levels.
Approximately, 1/3 of the patients in the study manifested prolonged stable disease. These findings suggest that ATN-161 should be
investigated further as an antiangiogenic and antimetastatic cancer agent alone or with chemotherapy.
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Angiogenesis is a requirement for the growth of nearly all tumours
and most metastases (Folkman, 1995; Carmeliet and Jain, 2000).
Regulatory molecules influencing endothelial cell behaviour
include: (1) circulating cytokines and growth factors, (2) extra-
cellular matrix (ECM) components and (3) membrane-bound
proteins. Antiangiogenic therapy could theoretically target any
step in the angiogenic process (Folkman, 1995; Harris, 1997).
Fibronectin is a component of the ECM that is also found at high
concentrations in plasma. Fibronectin interacts with a variety of
cell types including endothelial cells and regulates adhesion,
growth and migration through binding to the integrin family of
transmembrane proteins. Integrins are heterodimeric cell surface
receptors comprised of a and b subunits that mediate endothelial
cell proliferation and migration, both crucial features of neovessel
establishment (Brooks et al, 1994a,b; Brooks, 1996; Mitjans et al,
2000). The central cell-binding domain of fibronectin contains the
RGD recognition sequence required for binding to a5b1 integrin
(Pierschbacher and Ruoslahti, 1984) and the PHSRN synergy
sequence that increases the affinity and specificity of RGD-
mediated binding. (Aota et al, 1994; Mould et al, 1997) An
unregulated invasive response to the PHSRN synergy sequence
may contribute significantly to the growth, survival and metastasis
of established tumours.(Livant et al, 2000a) The role of the PHSRN
sequence in promoting tumour invasion and angiogenesis makes it
an appealing target for cancer therapy.
ATN-161 is a noncompetitive inhibitor of the fibronectin PHSRN
sequence, in which a cysteine residue has been substituted for
arginine along with peptide acetylation and amidation in order to
yield a product with acceptable pharmaceutical properties
(Ac-PHSCN-NH2). Unlike other integrin antagonists ATN-161 does
not block integrin-dependent adhesion, but may inhibit integrin-
dependent signalling as part of its mechanism of action (Plunkett
and Mazar, 2002; Plunkett et al, 2002). Recent studies show that
ATN-161 binds exclusively to integrin beta subunits (Donate et al,
2003). Thus, ATN-161 may inhibit the function of several integrins
implicated in tumour angiogenesis and metastasis. Disulphide
interchange has been proposed to mediate integrin activation (Yan
and Smith, 2000); we hypothesise that the free cysteine thiol in
ATN-161 blocks this interchange by forming a disulphide with the
integrin target, thereby suppressing integrin function.
In vitro, ATN-161 inhibited PHSRN-induced basement mem-
brane invasion of human (DU145) and rat (MLL) prostate cancer
cell lines (Livant et al, 2000b). In vivo, systemic administration of
5mgkg
 1 ATN-161 (five injections over 16 days) to Copenhagen
rats markedly reduced the growth of primary MLL tumours.
Furthermore, immunostaining of tumour sections from treated
and untreated rats suggested that blood vessel density in tumour
tissue from ATN-161-treated animals was eight- to 10-fold lower
on Day 16 than in tumour tissue from untreated animals. ATN-161
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salso inhibited the ability of MLL tumour cells to metastasise.
Attempts to show induction of apoptosis in MLL cells by ATN-161
were unsuccessful, suggesting that the inhibitory effects of ATN-
161 on primary tumour growth and metastasis formation were the
result of inhibition of new blood vessel growth rather than a direct
effect on tumour cells. We have also generated preclinical data
showing additive effects with diverse chemotherapy agents
(Plunkett et al, 2002; Plunkett et al, 2003; Stoeltzing et al, 2003).
ATN-161 was not immunogenic in animal studies.
In preclinical efficacy models ATN-161 exhibited a U-shaped
(inverted bell shape) dose–response curve. These preclinical
animal models included assessment of the effects of ATN-161 on
tumour growth, metastasis, angiogenesis, tumour perfusion and
circulating endothelial progenitor cells (CEPs) (Donate et al, 2003).
Preclinical toxicology studies showed no consistent evidence of
ATN-161 toxicity in rats or primates except at extremely high,
supratherapeutic doses. We designed the phase 1 trial to evaluate a
dose range in human beings (using well-established rules for
interspecies dose conversion (Freireich et al, 1966)) that would
cover adequately the broad trough of the U-shaped dose–response
curve.
This phase 1 clinical trial is the first study of this novel peptide
in humans. The thrice-weekly i.v. infusion schedule was chosen
because in murine studies frequent dosing was more efficacious
than intermittent dosing with little difference between dosing daily
and three times per week. The study also aimed to describe any
dose-limiting toxicities (DLTs) of ATN-161 and to verify the
absence of a maximum tolerated dose (MTD) in the chosen dose
range. Secondary objectives of the trial were to assess the
pharmacokinetics (PKs) of ATN-161 and to describe any
preliminary evidence of antitumour activity.
PATIENTS AND METHODS
Patient selection
Patients were eligible if they had a histologically or cytologically
confirmed nonhaematologic malignancy that was either unrespon-
sive to standard therapies or for which there was no known
effective therapy. Patients with measurable and nonmeasurable
disease were eligible. Other eligibility criteria included the
following: Eastern Cooperative Oncology Group performance
status (ECOG PS) p2 (Oken et al, 1982), age X18 years, adequate
haematologic variables (absolute neutrophil count X1500
cellsmm
 3, platelet count X100000 cellsmm
 3), adequate hepatic
function (total bilirubin p1.8mgdl
 1 and transaminase levels
p2.5 times the institutional upper limits of normal (ULN) (p5
times ULN for patients with liver metastases)), and adequate renal
function (serum creatinine p1.5 times the institutional ULN).
Prior chemo- or radiation therapy or immunotherapy was allowed
more than 4 weeks before Day 1 of study treatment (6 weeks for
nitrosoureas, mitomycin-C and liposomal doxorubicin). Treat-
ment-related toxicities of any prior therapies, including surgery,
must have resolved to Grade 1 or less prior to Day 1 of study
treatment. Exclusion criteria included the following: pregnant or
nursing women; men who had not had a vasectomy or were not
using birth control; patients with an active, unresolved infection or
who had received antibiotics within 7 days of the start of study
treatment; patients with carcinomatous meningitis or untreated/
uncontrolled metastatic parenchymal brain disease. Patients with a
prior history of parenchymal brain disease, which had been
controlled with appropriate therapy, were eligible if at least 8
weeks had passed since completion of therapy, and the patient was
asymptomatic and off corticosteroids. The Fox Chase Cancer
Center Institutional Review Board (IRB) approved the study
protocol and all patients signed an IRB-approved written informed
consent prior to study procedures and treatment.
Treatment plan and study design
ATN-161 was supplied as a sterile-filled, lyophilised powder in
glass vials (5ml), which contained 100mg ATN-161 for injection,
100mg glycine and 50mmol sodium citrate (pH adjusted to pH
5.0. using NaOH prior to lyophilisation). Each vial of ATN-161 for
injection was reconstituted to 2ml using sterile water for injection,
and then diluted in i.v. bags containing 50 or 100ml of sterile
normal saline USP.
ATN-161 was administered as a 10-min infusion, three times per
week. Sequential cohorts of three patients were enrolled to eight
different dose levels (0.1, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and
16.0mgkg
 1). All patients in a given dose level were evaluated
for at least 28 days before patients could be treated at the next
higher dose level. Patients receiving therapy for o1 cycle (4 weeks)
were to be replaced unless they had experienced a DLT. Toxicity
was evaluated according to the NCI Common Terminology Criteria
(CTC) Version 2.0. Dose-limiting toxicities were defined as any of
the following treatment-related events occurring during the first
cycle of therapy: Grade 4 neutropenia or febrile neutropenia, any
other Grade 3 or greater nonhaematologic toxicity, or any toxicity
requiring ATN-161 to be held for more than 1 week (i.e., three
consecutive missed doses). In the event of DLT, dosing was to be
held until recovery to at least Grade 1 toxicity and a new dosing
cycle for that patient was to be initiated at the investigator’s
discretion at 50% of the previous dose. If recovery did not occur
within 1 week (three missed doses), however, study treatment
was to be discontinued. In the event of Grade 2 toxicity involving
vital organs (hepatic, pulmonary, renal, neurologic, gastrointest-
inal or cardiotoxicity), the dose of ATN-161 was to be held until
recovery to Grade 0–1 before a new cycle was initiated at 100%
dosing. If the Grade 2 toxicity recurred, dosing was to be held until
recovery to Grade 0–1 and the next cycle would resume at 50%.
Occurrence of DLT at a given dose level would require further
enrolment of up to six patients at that dose level to determine if the
MTD had been exceeded. The MTD was defined as one dose level
below which X2/6 patients experienced a DLT. Treatment could
continue until progressive disease, or one of the following:
unacceptable toxicity, intercurrent illness, patient declined further
treatment, or physician decision in view of a patient’s other
medical conditions.
Patient evaluation
Pretreatment evaluations were performed within 14 days
prior to therapy, except for X-rays and scans, which were
performed within 28 days before therapy. Initial patient assess-
ments included a complete history and physical examination,
including neurological examination, weight, vital signs, ECOG PS,
chest X-ray, electrocardiogram, complete blood cell count
with differential and platelets, lactate dehydrogenase, glucose,
electrolytes, albumin, blood urea nitrogen, creatinine,
aspartate aminotransferase (serum glutamic oxaloacetic transami-
nase), alanine aminotransferase (serum glutamic pyruvic transa-
minase), alkaline phosphatase, total bilirubin, magnesium,
calcium, phosphorus, triglycerides, fibrinogen, PT and partial
thromboplastin time, and a complete urinalysis. For women of
childbearing potential, a negative serum pregnancy test was
documented within 72h prior to the start of treatment. Tumour
assessments were by physical examination, CT scan and/or MRI, as
appropriate.
During treatment, patients were evaluated monthly with
physical examinations including toxicity assessment using the
CTC, ECOG PS, serum chemistry, haematology and coagulation
testing. Tumour burden was reassessed every two cycles (8 weeks)
by physical exam or radiological methods as appropriate using
RECIST (Therasse et al, 2000).
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sPharmacokinetic sampling and analysis
Blood samples for PK analysis were collected in EDTA-coated
tubes on Day 1 for all patients preinfusion, at the end of infusion,
and at 5, 10, 15, 30, 45, 60, 90, 120, 150, 180, 240, 400, 460 and
520min after infusion. Samples were immediately centrifuged, and
the plasma was separated and stored at  201C prior to analysis. To
determine renal clearance (CLr) of ATN-161, urine samples were
also collected on Day 1 over the same 7-h postdose period. Plasma
and urine were analysed for ATN-161 by HPLC-MS/MS assays. The
measured concentration was the sum of free ATN-161, dimerised
ATN-161, and protein-bound ATN-161 after incubation with a
tris(carboxyethyl)phosphine solution.
Pharmacokinetic data were modelled using a noncompartmental
approach to estimate individual subject values for the following
parameters: maximum observed concentration (Cmax), time of the
maximum observed concentration (Tmax), volume of distribution
at steady state (VSS), terminal elimination half-life (t1/2), total
systemic clearance (CL), area under the plasma concentration-time
curve (AUC), and CLr. For these parameters the mean and s.d.
coefficient of variation were calculated.
Statistical analysis
No inferential analyses were performed. Data are presented in a
descriptive fashion. Treatment-emergent adverse events were
translated from investigator terms to MedDRA terminology and
summarised within and across dose levels for all patients who
received at least one dose of ATN-161. Treatment administration is
described for all patients, including drug/dose administration,
number of cycles, dose modifications or delays and duration of
therapy.
Descriptive PKs parameters were determined by standard model
independent methods for infusion administration (Perrier and
Gibaldi, 1982) from plasma concentrations in each individual
patient. Plasma and urine concentrations were rounded to the
nearest 1
10ngml
 1 before the calculations. Plasma samples with
concentrations below the quantifiable limit of 50.0ngml
 1 (BQL)
were assigned values of zero for generation of mean and s.d.
plasma concentrations. For PKs calculations, BQL was treated as
zero up to the first quantifiable plasma concentration and then
treated as an empty value thereafter. Urine samples reported as
BQL (p50.0ngml
 1) were treated as zero for all calculations.
Actual patient blood collection sampling times relative to the start
of infusion were used for PKs calculations; however, scheduled
collection times were used for urinary excretion data and graphical
presentations of all data.
RESULTS
Patient characteristics
As shown in Table 1, 26 adult patients were enrolled into the study
from January 2003 to October 2004 at the Fox Chase Cancer
Center. The median age for all patients was 64 years (range 26–91
years), and there were 15 males and 11 females. All patients had
pathological diagnoses of cancer as indicated. Most patients were
heavily pretreated but three patients had received no prior
chemotherapy (although each had received radiation or biologic
therapy). The majority of patients had an ECOG PS of 1. Three
patients were enrolled in each cohort except for the 0.25 and
1.0mgkg
 1 cohorts, into which an additional patient was enrolled
as a replacement for a patient who withdrew prematurely from the
study (for reasons other than toxicity).
Toxicity
Table 2 shows the eight dose levels for the study and all adverse
events at each dose level in any course of treatment. Few adverse
events were considered treatment related and none of these events
was considered both serious and treatment associated at any of the
dose levels tested. All of the treatment-related adverse events were
Grade 2 or less and no DLTs occurred. There was no indication
that the incidence or severity of adverse events increased at higher
Table 1 Patient characteristics (N¼26)
Sex (N)
Men 15
Women 11
Age, years
Median 64
Min–max (26–91)
Number of prior chemotherapy regimens
03
a
17
24
X31 2
ECOG performance status
06
11 5
25
Tumour type/tumour location (N)
Prostate 4
Hepatocellular 3
Colon 2
Renal cell 2
Other, one each
b 15
aAdenoid cystic cancer treated with surgery and radiation, renal cell cancers treated
with immunotherapy and anti-EGFR monoclonal antibody.
bAdenoid cystic carcinoma
of hard palate, ameloblastoma, breast, carcinoid neuroendocrine tumour, oesopha-
geal, liposarcoma, Merkel cell, non-small-cell lung cancer, osteosarcoma, ovarian
(granulosa cell), pancreatic, primitive neuroectodermal tumour (kidney), pseudomyx-
oma peritonei, thyroid, unknown primary.
Table 2 ATN-161-associated
a adverse events by dose level
MedDRA preferred term Number of patients
0.5mgkg
 1 1
Muscle cramps 1
Sweating increased 1
1.0mgkg
 1 1
Dry mouth 1
Cellulitis 1
Pain in limb 1
Paresthesia 1
Phlebitis not otherwise specified (NOS) 1
2.0mgkg
 1 2
Oral candidiasis 1
Anemia NOS 1
Hypotension NOS 1
4.0mgkg
 1 2
Nausea 2
Constipation 1
Fatigue 1
8.0mgkg
 1 1
Nausea 1
16.0mgkg
 1 1
Hypotension NOS 1
aPossible, probable or definite relationship to study medication according to the
investigator.
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sdoses or that side effects emerged or became worse with continued
chronic dosing. A MTD was not reached at 16mgkg
 1, which was
therefore designated as the maximum administered dose. One
patient at the 8mgkg
 1 dose level died suddenly during Cycle 2.
The event was felt due to underlying cardiac disease and not to
protocol therapy. No autopsy was performed, however, and
therefore a precise cause of death was not determined.
Pharmacokinetics
Pharmacokinetics data were obtained from all patients treated with
ATN-161. At the lowest dose level of 0.1mgkg
 1, ATN-161 was
detected only at the earliest plasma sampling time points (up to
15min postinfusion); therefore, data from that dose level are not
included in the PK summary in Table 3. Pharmacokinetic data at
doses of 0.25 and 0.5mgkg
 1 showed considerable interpatient
variability, in part due to undetectable plasma concentrations at
later time sampling points. At dose levels 1.0, 2.0 and 4.0mgkg
 1,
PK parameters appear to be dose independent. At the 8 and
16mgkg
 1 dose levels, Cmax and AUCs were increased, and total
clearance was reduced, suggesting saturable elimination. The
observed half-life was 3.2–5.0h. At doses of ATN-161 above
0.5mgkg
 1, t1/2 values showed little variability. There was no
serological evidence for an antibody immune response against
ATN-161.
Urinary excretion of ATN-161 accounted for approximately 2%
of the administered ATN-161 dose in the majority of the patients
(20 of 26) and between 20 and 50% of the dose in the remaining six
patients. This dichotomy in excretion percentages was not
associated with dose level. In almost all patients (23 of 26), the
majority of the dose was excreted during the first 2h following
dose administration. Mean CLr of ATN-161 ranged from 18.2 to
52.4mlmin
 1 across all dose groups.
Clinical response
Table 4 shows the duration of treatment and clinical response for
all patients treated. No patient in the study had an objective
response as defined by RECIST. The median number of cycles
received was 2, which corresponded to 8 weeks of treatment.
Treatment duration ranged from o1 to 14 cycles. There was no
apparent correlation between clinical benefit and dose level nor
was there a clear association between length of time on study and
dose level. Among the 26 treated patients, six (23%) experienced
stable disease of 44 months and three of those patients received
10 or more cycles (Table 4). Four patients with prolonged stable
disease had well-documented progressive disease prior to study
entry (one case each of adenoid cystic, renal cell, prostate and
ovarian cancer).
DISCUSSION
We report here the results of a first-in-humans phase 1, dose
escalation, PKs study of thrice weekly i.v. ATN-161 in patients with
advanced cancer. Patients were treated at doses ranging from 0.1 to
16mgkg
 1. Our study demonstrates that treatment with ATN-161
was without significant toxicity in the assessed dose range; we have
defined 16mgkg
 1 as the maximum administered dose. There
were no objective clinical responses.
Pharmacokinetics data showed rapid clearance from plasma and
a Vss indicating high tissue distribution. Despite a very short half-
life, ATN-161 appeared to have a durable effect in suppressing
tumour growth in preclinical model systems such that it only
needs to be administered intermittently (rather than continu-
ously). We therefore hypothesise either that the peptide is retained
on its receptor for a period of time (consistent with the hypothesis
that ATN-161 forms a disulphide bond with its target integrin) or
that ATN-161 otherwise elicits a long-lived response. Studies are
currently underway in preclinical models to evaluate these
hypotheses. ATN-161 was not immunogenic in humans, confirm-
ing the preclinical animal observations, and indicating that
immunogenicity does not explain the short half-life.
We did not determine a traditional MTD for ATN-161. The dose
range for the phase 1 trial was chosen to bracket the most active
portion (trough) of the U, converting the active dose range from
mouse to man using well-established rules of interspecies dose
conversion (Freireich et al, 1966). Given the shape of the
Table 3 Pharmacokinetic properties of ATN-161 in patients*
Dose (mgkg
 1)
Parameter 0.1 0.25 0.5 1 2 4 8 16
Dose level I II III IV V VI VII VIII
Cmax (ngml
 1) 236.0 1119.9 5785.5 3800.5 15730.8 5476.3 34414.1 72673.1
AUC(0-7) (nghml
 1) ND 3415.1 3608.2 1446.3 3317.0 3712.8 34216.9 54927.5
AUC(0-24) (ngh
 1ml
 1) ND 5108.5 4302.6 1759.0 3672.7 4726.3 40774.2 74203.3
AUC(0-inf) (ngh
 1ml
 1) ND 5394.6 4382.6 1781.3 3693.9 4915.1 41045.1 78754.8
CL (lh
 1kg
 1) ND 0.08 0.17 0.61 0.69 0.87 0.42 0.35
CLr (lh
 1kg
 1) ND 0.024 0.031 0.014 0.019 0.026 0.030 0.033
CLr (mlmin
 1) ND 23.33 52.38 18.16 23.25 29.61 35.73 48.09
Vd (lkg
 1) ND 0.48 0.87 3.38 3.38 5.59 2.14 2.36
Vss (lkg
 1) ND 0.33 0.47 2.30 1.93 3.82 1.32 1.61
MRT(INF) (h) ND 5.5 3.3 3.8 2.5 4.8 3.4 5.3
Urinary excretion (%) 2.46 13.79 25.31 1.82 2.35 2.36 17.49 15.26
T1/2
a (h) ND 4.4 3.2 3.9 3.5 4.3 3.3 5.0
*All values represent the mean (s.d.) except for T1/2. ND, not determined; CL, systemic clearance; CLr, renal clearance; Vd, volume of distribution; Vdss, volume of distribution at
steady-state; MRT(INF), mean residence time; urinary excretion, urinary excretion between 0 and 7h as a percent of dose.
aExpressed as harmonic mean.
Table 4 Number of cycles administered
Number
of cycles
Dose level
(mgkg
 1) Number of patients
p2 0.1–16.0 16
42–p4 0.1–1.0 4
4.5 0.5 1: prostate
5 2.0 1: pseudomyxoma peritonei
6 16.0 1: ameloblastoma
10 0.1 1: ovarian granulosa cell tumour
11 2.0 1: renal cell
14 1.0 1: adenoid cystic of hard palate
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spreclinical dose–response curve there would, in fact, be no
purpose in aiming for or achieving a traditional MTD. The absence
of an MTD, of course, makes dose selection for phase 2 studies
challenging. We believe the efficacious dose range was probably
covered by the doses evaluated in the phase 1 study; each of these
doses was safe. In future studies in phase 2 patient populations
that are more homogeneous for disease, stage, and prior treatment
history, we will assess biomarkers such as CEPs (Bertolini et al,
2003), and dce-MRI (Galbraith et al, 2003; Liu et al, 2005) to refine
dose selection. Preclinical studies of ATN-161, for example, suggest
that at least one of these biomarkers also exhibits a U-shape in the
response to ATN-161. (Hensley and Mazar, 2003)
U-shaped dose response curves (low-dose stimulation and high-
dose inhibition) occur in other systems, including studies of
chemotherapeutic agents (Calabrese and Baldwin, 2002, 2003). At
least one set of empiric observations in the angiogenesis field
suggests that interferon alpha at a low dose rather than a maximal
tolerated dose has the most potent clinical effects (Drolet et al,
1999; Slaton et al, 1999). Similar dose–response curves have been
described for immunocytokines (Kopp et al, 1993; Talmadge, 1998;
Curnis et al, 2005). Phase 1 clinical trials experts have suggested
that an MTD-seeking approach may not be appropriate for
antineoplastic agents with mechanisms of action that are distinct
from conventional cytotoxic drugs (Parulekar and Eisenhauer,
2004).
ATN-161 is the first inhibitor of the PHSRN synergy sequence to
be evaluated in a clinical trial. There are published studies of other
agents that target integrins for cancer therapy, including MEDI-
532 (Vitaxint, an anti-avb3 antibody) (Gutheil et al, 2000) and
cilengitide (EMD 121974, a cyclised pentapeptide that is a potent
and selective antagonist for integrins avb3 and avb5) (Eskens et al,
2000). As we observed with ATN-161, integrin antagonists with
diverse molecular structures are safe and potentially active without
evidence for dose-limiting toxicity. Interestingly, there were no
objective responses to any of these agents, but there were
descriptions of prolonged stable disease, especially in patients
with renal cell cancer (Eskens et al, 2000).
The safety and tolerability of ATN-161 in this study and
preliminary evidence of possible biologic effect (prolonged stable
disease) suggest that further clinical studies of this agent are
warranted. Similar to the clinical development of other agents such
as bevacizumab (Hurwitz et al, 2004; Wakelee and Schiller, 2005;
Ahmed et al, 2004; Rini et al, 2005; Sledge, 2005), the best
approach for phase 2 studies will be combinations of ATN-161
with chemotherapy rather than development as a single agent
(Plunkett et al, 2002, 2003; Stoeltzing et al, 2003).
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